G protein-coupled receptor 62Genealiases: GPCR8 · KPG_005
Q-omics provides the consensus-scored GPR62 profile across patient tissues and cancer cell-line models. GPR62 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPR62 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GPR62 RNA expression shows 16,354 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where GPR62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR62 survival associations across molecular data types. GPR62 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR62 RNA expression–survival associations across cancer types. High GPR62 expression shows favorable associations in KIRP, UVM, HNSC, THCA, UCS and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPR62 RNA expression.
This table summarizes GPR62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR62 shows lower tumor expression in KIRC, KICH, KIRP, BRCA, READ and UCEC. The KIRC box plot shows higher GPR62 RNA expression in normal versus tumor tissue (log2 FC = −0.531, t-test p < 0.001).
This table shows molecular features associated with GPR62 in patient tissues and cancer cell lines. In patient samples, GPR62 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
